Name | A2ti-1 |
---|
Description | A2ti-1 is a selective and high-affinity annexin A2/S100A10 heterotetramer (A2t) inhibitor with an IC50 of 24 μM[1]. A2ti-1 specifically disrupts the protein-protein interaction (PPI) between A2 and S100A10. A2ti-1 prevents human papillomavirus type 16 (HPV16) infection[2]. |
---|---|
Related Catalog | |
Target |
IC50: 24 μM (A2t)[1] |
In Vitro | A2ti-1 (compound 1 b) is an annexin A2-S100A10 protein-protein interaction blocker[1]. A2ti-1 (100 μM; for 72 hours) reduces HPV16 PsV infection of HeLa cells in a dose-dependent manner[2]. A2ti-1 (10, 25, 50, 75, 100 μM; 24 hours) significantly reduces CFDA-SE-labelled HPV16 PsV entry into HeLa cells in a dose-dependent manner[2]. Cell Viability Assay[2] Cell Line: HeLa cells Concentration: 100 μM Incubation Time: For 72 hours Result: Reduced HPV16 PsV infection of HeLa cells in a dose-dependent manner with 100% inhibition of infection observed at 100 μM and similar results were observed in HaCaT cells. |
References |
Molecular Formula | C20H22N4O2S |
---|---|
Molecular Weight | 382.48 |